In $23M deal, Syn­cona adds ex-Bio­gen part­ner and 20-year-old gene ther­a­py out­fit AGTC to port­fo­lio

Syn­cona is bring­ing a long-time biotech, with no ap­proved ther­a­pies yet, in­to its fold.

The long­time UK life sci­ences in­vestor, back­ing com­pa­nies such as Force­field Ther­a­peu­tics and more than 10 oth­ers, put out word Mon­day that it is bring­ing in a new gene ther­a­py com­pa­ny un­der its wing through a new Syn­cona sub­sidiary. The play­er? Ap­plied Ge­net­ic Tech­nolo­gies Cor­po­ra­tion, which got start­ed back in 1999.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER